In addition, we demonstrated the sensitivity of the EGFR-mutant NSCLC organoid culture TH107 (EGFRdel19) to treatment with the FAK inhibitor VS-4718 in combination with osimertinib (Fig. 4c). The gene discussed is PTK2; the disease is non-small cell lung carcinoma.